PL4185292T3 - Białka s100 jako nowe cele terapeutyczne w przypadku nowotworów mieloproliferacyjnych - Google Patents
Białka s100 jako nowe cele terapeutyczne w przypadku nowotworów mieloproliferacyjnychInfo
- Publication number
- PL4185292T3 PL4185292T3 PL21749566.2T PL21749566T PL4185292T3 PL 4185292 T3 PL4185292 T3 PL 4185292T3 PL 21749566 T PL21749566 T PL 21749566T PL 4185292 T3 PL4185292 T3 PL 4185292T3
- Authority
- PL
- Poland
- Prior art keywords
- proteins
- therapeutic targets
- novel therapeutic
- myeloproliferative neoplasms
- myeloproliferative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20187323 | 2020-07-23 | ||
| PCT/EP2021/070629 WO2022018240A1 (en) | 2020-07-23 | 2021-07-23 | S100 proteins as novel therapeutic targets in myeloproliferative neoplasms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4185292T3 true PL4185292T3 (pl) | 2025-10-13 |
Family
ID=71783860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21749566.2T PL4185292T3 (pl) | 2020-07-23 | 2021-07-23 | Białka s100 jako nowe cele terapeutyczne w przypadku nowotworów mieloproliferacyjnych |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230293512A1 (pl) |
| EP (2) | EP4185292B1 (pl) |
| JP (1) | JP7747732B2 (pl) |
| KR (1) | KR20230043916A (pl) |
| CN (1) | CN116782902A (pl) |
| AU (1) | AU2021313388A1 (pl) |
| BR (1) | BR112023000892A2 (pl) |
| CA (1) | CA3185531A1 (pl) |
| ES (1) | ES3037361T3 (pl) |
| IL (1) | IL300068A (pl) |
| MX (1) | MX2023000903A (pl) |
| PL (1) | PL4185292T3 (pl) |
| WO (1) | WO2022018240A1 (pl) |
| ZA (1) | ZA202301267B (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117295492A (zh) | 2021-05-25 | 2023-12-26 | 活跃生物技术有限公司 | 多个他喹莫德粒子及其用途 |
| JP2024524158A (ja) | 2021-07-02 | 2024-07-05 | アクティブ バイオテック エイビー | タスキニモドを含有する医薬製品および前記製品の純度を評価する方法 |
| CN114848826B (zh) * | 2022-07-06 | 2023-03-28 | 北京天宇恒泰科技有限公司 | 用于治疗胰腺癌的组合物及用途和评价系统 |
| AU2024306742A1 (en) * | 2023-06-28 | 2025-12-04 | Active Biotech Ab | Quinoline carboxamides for use in the treatment of mpn |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| US20100021472A1 (en) * | 2008-07-25 | 2010-01-28 | Geetha Srikrishna | Methods for diagnosing and treating cancer |
| DK2590949T5 (en) | 2010-07-09 | 2016-05-23 | Active Biotech Ab | METHOD OF PRODUCING quinoline-3-carboxamides |
| EP2537517A1 (en) | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
| EA030948B1 (ru) | 2014-09-23 | 2018-10-31 | Эктив Байотек Аб | Хинолинкарбоксамиды для применения в лечении множественной миеломы |
| EP3212239A1 (en) * | 2014-10-29 | 2017-09-06 | Westfälische Wilhelms-Universität Münster | Quinoline-3-carboxamide compounds and their use in diagnosis |
| EA031643B1 (ru) | 2014-11-19 | 2019-01-31 | Эктив Байотек Аб | Применение тасквинимода для лечения острого лимфобластного лейкоза и острого миелоидного лейкоза |
| US11359010B2 (en) | 2015-07-13 | 2022-06-14 | UNIVERSITé LAVAL | Humanized anti-S100A9 antibody and uses thereof |
| US20190218299A1 (en) * | 2016-05-19 | 2019-07-18 | Momenta Pharmaceuticals, Inc. | Methods for Treating Disorders Associated with Fibrosis and Systemic Sclerosis |
| US11554178B2 (en) * | 2017-06-30 | 2023-01-17 | City Of Hope | Compositions and methods of modulating macrophage activity |
-
2021
- 2021-07-23 KR KR1020237006110A patent/KR20230043916A/ko active Pending
- 2021-07-23 JP JP2023504279A patent/JP7747732B2/ja active Active
- 2021-07-23 US US18/017,078 patent/US20230293512A1/en active Pending
- 2021-07-23 CA CA3185531A patent/CA3185531A1/en active Pending
- 2021-07-23 AU AU2021313388A patent/AU2021313388A1/en active Pending
- 2021-07-23 ES ES21749566T patent/ES3037361T3/es active Active
- 2021-07-23 CN CN202180050063.6A patent/CN116782902A/zh active Pending
- 2021-07-23 PL PL21749566.2T patent/PL4185292T3/pl unknown
- 2021-07-23 BR BR112023000892A patent/BR112023000892A2/pt unknown
- 2021-07-23 WO PCT/EP2021/070629 patent/WO2022018240A1/en not_active Ceased
- 2021-07-23 IL IL300068A patent/IL300068A/en unknown
- 2021-07-23 EP EP21749566.2A patent/EP4185292B1/en active Active
- 2021-07-23 MX MX2023000903A patent/MX2023000903A/es unknown
- 2021-07-23 EP EP25177507.8A patent/EP4582448A3/en active Pending
-
2023
- 2023-01-31 ZA ZA2023/01267A patent/ZA202301267B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202301267B (en) | 2024-05-30 |
| BR112023000892A2 (pt) | 2023-02-07 |
| AU2021313388A1 (en) | 2023-01-19 |
| US20230293512A1 (en) | 2023-09-21 |
| ES3037361T3 (en) | 2025-10-01 |
| EP4582448A3 (en) | 2025-12-10 |
| WO2022018240A1 (en) | 2022-01-27 |
| KR20230043916A (ko) | 2023-03-31 |
| CA3185531A1 (en) | 2022-01-27 |
| EP4185292A1 (en) | 2023-05-31 |
| IL300068A (en) | 2023-03-01 |
| JP2023535021A (ja) | 2023-08-15 |
| CN116782902A (zh) | 2023-09-19 |
| EP4185292C0 (en) | 2025-05-21 |
| JP7747732B2 (ja) | 2025-10-01 |
| EP4185292B1 (en) | 2025-05-21 |
| MX2023000903A (es) | 2023-04-20 |
| EP4582448A2 (en) | 2025-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL4185292T3 (pl) | Białka s100 jako nowe cele terapeutyczne w przypadku nowotworów mieloproliferacyjnych | |
| CY1122165T1 (el) | Αντισωματα anti-cd38 | |
| CY1119960T1 (el) | Μεθοδοι για την αυξηση της αποτελεσματικοτητας της folr1 θεραπειας του καρκινου | |
| CY1117655T1 (el) | Παραγοντες οι οποιοι επαγουν αποπτωση για την αντιμετωπιση καρκινου και ανοσολογικων και αυτοανοσων νοσηματων | |
| CY1116728T1 (el) | Παραγοντες οι οποιοι επαγουν αποπτωση για την αντιμετωπιση καρκινου και ανοσολογικων και αυτοανοσων νοσηματων | |
| CY1117423T1 (el) | Παραγοντες που επηρεαζουν αποπτωση για τη θεραπεια καρκινου και ανοσων και αυτοανοσων ασθενειων | |
| PH12015502780A1 (en) | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | |
| MX366130B (es) | Inhibidores bivalentes de las proteinas iap y métodos terapéuticos que usan los mismos. | |
| PH12015500758A1 (en) | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | |
| MX370814B (es) | Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas. | |
| SG10201808102WA (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| IL231926A (en) | Factors that induce apoptosis for the treatment of cancer and autoimmune and autoimmune diseases and their pharmaceutical compositions | |
| EP3946410A4 (en) | Therapeutic interferon alpha 1 proteins | |
| WO2012170513A3 (en) | He4 based therapy for malignant disease | |
| IL291601B1 (en) | Neoglycoconjugates as vaccines and therapeutic tools | |
| PL3618848T3 (pl) | Biologicznie aktywne kompleksy i ich zastosowania terapeutyczne | |
| IL265719B1 (en) | Fabp4 as a therapeutic target in skin diseases | |
| IL290675A (en) | Medical protein concentrates | |
| BR112013012040A2 (pt) | tratamento de câncer com dosagens elevadas de proteínas de fusão fdfr1 solúveis | |
| IL285938B2 (en) | Human serum albumin in formulations | |
| SI2588480T1 (sl) | Derivati 3,4-dihidropirolo(1,2-a)pirazina-2,8(1H)-dikarboksamida, njihova priprava in terapevtska uporaba | |
| HK40092037A (zh) | 作为骨髓增殖性肿瘤的新治疗靶点的s100蛋白 | |
| IL280564A (en) | Selection of therapeutic proteins under simulated conditions in the living body | |
| EP3834826A4 (en) | THERAPEUTIC AGENT FOR HUMORAL IMMUNITY-RELATED DISEASES IN THE MATERNO-FETAL RELATIONSHIP | |
| PL3277687T3 (pl) | Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-a]pirymidyny użyteczne do leczenia chorób immunologicznych lub zapalnych lub nowotworów |